Provention Bio Resubmits BLA for Teplizumab to Delay Type 1 Diabetes

Provention Bio has resubmitted the Biologics License Application for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals.

Related Keywords

Ashleigh Palmer ,Provention Bio ,Provention Bio Inc ,Metabolic Drugs Advisory Committee ,Drug Administration ,Biologics License Application ,Complete Response Letter ,Breakthrough Therapy Designated ,Accessed February ,